Literature DB >> 23328585

Earlier detection of breast cancer with ultrasound molecular imaging in a transgenic mouse model.

Sunitha V Bachawal1, Kristin C Jensen, Amelie M Lutz, Sanjiv S Gambhir, Francois Tranquart, Lu Tian, Jürgen K Willmann.   

Abstract

While there is an increasing role of ultrasound for breast cancer screening in patients with dense breast, conventional anatomical ultrasound lacks sensitivity and specificity for early breast cancer detection. In this study, we assessed the potential of ultrasound molecular imaging using clinically translatable vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted microbubbles (MB(VEGFR2)) to improve the diagnostic accuracy of ultrasound in earlier detection of breast cancer and ductal carcinoma in situ (DCIS) in a transgenic mouse model [FVB/N-Tg(MMTV-PyMT)634Mul]. In vivo binding specificity studies (n = 26 tumors) showed that ultrasound imaging signal was significantly higher (P < 0.001) using MB(VEGFR2) than nontargeted microbubbles and imaging signal significantly decreased (P < 0.001) by blocking antibodies. Ultrasound molecular imaging signal significantly increased (P < 0.001) when breast tissue (n = 315 glands) progressed from normal [1.65 ± 0.17 arbitrary units (a.u.)] to hyperplasia (4.21 ± 1.16), DCIS (15.95 ± 1.31), and invasive cancer (78.1 ± 6.31) and highly correlated with ex vivo VEGFR2 expression [R(2) = 0.84; 95% confidence interval (CI), 0.72-0.91; P < 0.001]. At an imaging signal threshold of 4.6 a.u., ultrasound molecular imaging differentiated benign from malignant entities with a sensitivity of 84% (95% CI, 78-88) and specificity of 89% (95% CI, 81-94). In a prospective screening trail (n = 63 glands), diagnostic performance of detecting DCIS and breast cancer was assessed and two independent readers correctly diagnosed malignant disease in more than 95% of cases and highly agreed between each other [intraclass correlation coefficient (ICC) = 0.98; 95% CI, 97-99]. These results suggest that VEGFR2-targeted ultrasound molecular imaging allows highly accurate detection of DCIS and breast cancer in transgenic mice and may be a promising approach for early breast cancer detection in women.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328585      PMCID: PMC3602408          DOI: 10.1158/0008-5472.CAN-12-3391

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan.

Authors:  Z Garami; Z Hascsi; J Varga; T Dinya; M Tanyi; I Garai; L Damjanovich; L Galuska
Journal:  Eur J Surg Oncol       Date:  2011-09-19       Impact factor: 4.424

2.  Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes.

Authors:  J R Lindner; J Song; F Xu; A L Klibanov; K Singbartl; K Ley; S Kaul
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

3.  Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).

Authors:  Jessica Bzyl; Wiltrud Lederle; Anne Rix; Christoph Grouls; Isabelle Tardy; Sibylle Pochon; Monica Siepmann; Tobias Penzkofer; Michel Schneider; Fabian Kiessling; Moritz Palmowski
Journal:  Eur Radiol       Date:  2011-05-12       Impact factor: 5.315

4.  Quantification and monitoring of inflammation in murine inflammatory bowel disease with targeted contrast-enhanced US.

Authors:  Nirupama Deshpande; Amelie M Lutz; Ying Ren; Kira Foygel; Lu Tian; Michel Schneider; Reetesh Pai; Pankaj J Pasricha; Jürgen K Willmann
Journal:  Radiology       Date:  2011-11-04       Impact factor: 11.105

Review 5.  Targeted contrast-enhanced ultrasound: an emerging technology in abdominal and pelvic imaging.

Authors:  Marybeth A Pysz; Jürgen K Willmann
Journal:  Gastroenterology       Date:  2011-01-18       Impact factor: 22.682

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography.

Authors:  W Buchberger; A Niehoff; P Obrist; P DeKoekkoek-Doll; M Dünser
Journal:  Semin Ultrasound CT MR       Date:  2000-08       Impact factor: 1.875

8.  Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results.

Authors:  C K Kuhl; R K Schmutzler; C C Leutner; A Kempe; E Wardelmann; A Hocke; M Maringa; U Pfeifer; D Krebs; H H Schild
Journal:  Radiology       Date:  2000-04       Impact factor: 11.105

9.  Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.

Authors:  Isabelle Tardy; Sibylle Pochon; Martine Theraulaz; Patricia Emmel; Lisa Passantino; François Tranquart; Michel Schneider
Journal:  Invest Radiol       Date:  2010-10       Impact factor: 6.016

Review 10.  Supplementary screening sonography in mammographically dense breast: pros and cons.

Authors:  Ji Hyun Youk; Eun-Kyung Kim
Journal:  Korean J Radiol       Date:  2010-10-29       Impact factor: 3.500

View more
  41 in total

1.  High-frequency Ultrasound Imaging of Mouse Cervical Lymph Nodes.

Authors:  Elyse L Walk; Sarah L McLaughlin; Scott A Weed
Journal:  J Vis Exp       Date:  2015-07-25       Impact factor: 1.355

2.  Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression.

Authors:  Sunitha Bachawal; Gregory R Bean; Gregor Krings; Katheryne E Wilson
Journal:  NPJ Breast Cancer       Date:  2020-04-29

3.  Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection.

Authors:  Rakesh Bam; Patrick S Lown; Lawrence A Stern; Karina Sharma; Katheryne E Wilson; Gregory R Bean; Amelie M Lutz; Ramasamy Paulmurugan; Benjamin J Hackel; Jeremy Dahl; Lotfi Abou-Elkacem
Journal:  Clin Cancer Res       Date:  2020-01-10       Impact factor: 12.531

4.  The Use of Acoustic Radiation Force Decorrelation-Weighted Pulse Inversion for Enhanced Ultrasound Contrast Imaging.

Authors:  Elizabeth B Herbst; Sunil Unnikrishnan; Shiying Wang; Alexander L Klibanov; John A Hossack; Frank William Mauldin
Journal:  Invest Radiol       Date:  2017-02       Impact factor: 6.016

Review 5.  Ultrasound molecular imaging: Moving toward clinical translation.

Authors:  Lotfi Abou-Elkacem; Sunitha V Bachawal; Jürgen K Willmann
Journal:  Eur J Radiol       Date:  2015-03-21       Impact factor: 3.528

6.  Improved Sensitivity in Ultrasound Molecular Imaging With Coherence-Based Beamforming.

Authors:  Dongwoon Hyun; Lotfi Abou-Elkacem; Valerie A Perez; Sayan Mullick Chowdhury; Juergen K Willmann; Jeremy J Dahl
Journal:  IEEE Trans Med Imaging       Date:  2018-01       Impact factor: 10.048

7.  Nondestructive Detection of Targeted Microbubbles Using Dual-Mode Data and Deep Learning for Real-Time Ultrasound Molecular Imaging.

Authors:  Dongwoon Hyun; Lotfi Abou-Elkacem; Rakesh Bam; Leandra L Brickson; Carl D Herickhoff; Jeremy J Dahl
Journal:  IEEE Trans Med Imaging       Date:  2020-04-09       Impact factor: 10.048

8.  A novel dual-targeted ultrasound contrast agent provides improvement of gene delivery efficiency in vitro.

Authors:  Jinfeng Xu; Xinxin Zeng; Yingying Liu; Hui Luo; Zhanghong Wei; Huiyu Liu; Yuli Zhou; Hairong Zheng; Jie Zhou; Guanghong Tan; Fei Yan
Journal:  Tumour Biol       Date:  2016-01-06

9.  Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.

Authors:  Paul F Laeseke; Ru Chen; R Brooke Jeffrey; Teresa A Brentnall; Jürgen K Willmann
Journal:  Radiology       Date:  2015-12       Impact factor: 11.105

10.  Ultra-Low-Dose Ultrasound Molecular Imaging for the Detection of Angiogenesis in a Mouse Murine Tumor Model: How Little Can We See?

Authors:  Shiying Wang; Elizabeth B Herbst; F William Mauldin; Galina B Diakova; Alexander L Klibanov; John A Hossack
Journal:  Invest Radiol       Date:  2016-12       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.